Featured Research

from universities, journals, and other organizations

Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients

Date:
March 26, 2010
Source:
ECCO-the European CanCer Organisation
Summary:
In patients with early breast cancer, giving radiotherapy to the lymph nodes located behind the breast bone and above the collar bone is well-tolerated, after mastectomy or breast conserving surgery, says a large international study. Women at a high risk of developing breast cancer will probably benefit from additional lymph node radiotherapy. The study found that there is no evidence of increased toxicity to the heart at three years follow-up.

In patients with early breast cancer, giving radiotherapy to the lymph nodes located behind the breast bone and above the collar bone is well-tolerated, after mastectomy or breast conserving surgery, a radiation oncologist told delegates at the seventh European Breast Cancer Conference (EBCC7) on March 27. Women at a high risk of developing breast cancer will probably benefit from additional lymph node radiotherapy, Dr Philip Poortmans, from the Dr. Bernard Verbeeten Instituut, Tilburg, The Netherlands, and a member of the EORTC* Radiation Oncology Group, said.

Initial findings from the 4,004-patient multi-centre study carried out by the EORTC radiotherapy and breast cancer groups (46 institutions from 13 countries) show that there is no evidence of increased toxicity to the heart at three years follow-up in patients who received additional lymph node radiotherapy.

Patients will be followed-up for many years to see whether specific lymph-node radiotherapy could lead to long-term damage of the heart or the lungs, side effects that are associated with breast cancer radiotherapy.

Dr Philip Poortmans, one of the trial co-ordinators, told delegates that the longer-term aim of the EORTC study is to see whether giving additional radiotherapy to the lymph nodes located behind the breast bone and above the collar bone (internal mammary and medial supraclavicular [IM-MS] lymph nodes) to patients with early operable breast cancer will improve overall survival.

"The first analysis of the primary endpoint, overall survival at 10 years, was planned to be performed in 2012. However, thanks to the actual survival estimate that is even higher than expected, this might have to be postponed until 2014," Dr Poortmans said.

"We are hopeful that we will see a survival benefit of at least five percent in patients at the time of the primary analysis," Dr Poortmans said. "With a median follow-up of over seven years, 558 patients have died, so the estimated 10-year overall survival rate of 79%-83% is even above the anticipated range," he added.

The majority of patients (76%) had breast-conserving surgery and the remainder had undergone complete removal of their breast (24%). All patients (99.4%) who had breast-conserving surgery received standard radiotherapy to the breast as well as a boost, and 73% of mastectomy treated patients received chest wall radiotherapy. Following this, patients were randomised to receive IM-MS lymph node radiotherapy or no further lymph node therapy.

Radiotherapy is usually given after breast cancer surgery to destroy any cancer cells that remain in the breast, chest wall, or underarm area, in order to reduce the risk of a local recurrence of cancer in that breast. But there is disagreement amongst cancer experts regarding the management of the internal mammary lymph nodes (lymph nodes located behind the breast bone) in patients with breast cancer. The question of whether specific internal mammary lymph node radiotherapy leads to improved survival in women with early breast cancer is currently being addressed by the EORTC radiotherapy and breast cancer groups.

Dr Poortmans said that the final overall survival data analysis will show if internal mammary lymph node radiotherapy provides local control and improves overall survival in women with early breast cancer. "This is an important issue for radiotherapists and breast cancer patients alike, and we are eagerly awaiting the efficacy results from this trial," he says.


Story Source:

The above story is based on materials provided by ECCO-the European CanCer Organisation. Note: Materials may be edited for content and length.


Cite This Page:

ECCO-the European CanCer Organisation. "Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients." ScienceDaily. ScienceDaily, 26 March 2010. <www.sciencedaily.com/releases/2010/03/100326213019.htm>.
ECCO-the European CanCer Organisation. (2010, March 26). Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/03/100326213019.htm
ECCO-the European CanCer Organisation. "Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/03/100326213019.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins